206 related articles for article (PubMed ID: 20858855)
1. Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells.
Wang X; Zhang W; Tripodi J; Lu M; Xu M; Najfeld V; Li Y; Hoffman R
Blood; 2010 Dec; 116(26):5972-82. PubMed ID: 20858855
[TBL] [Abstract][Full Text] [Related]
2. Correction of the abnormal trafficking of primary myelofibrosis CD34+ cells by treatment with chromatin-modifying agents.
Wang X; Zhang W; Ishii T; Sozer S; Wang J; Xu M; Hoffman R
Cancer Res; 2009 Oct; 69(19):7612-8. PubMed ID: 19752087
[TBL] [Abstract][Full Text] [Related]
3. Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis.
Shi J; Zhao Y; Ishii T; Hu W; Sozer S; Zhang W; Bruno E; Lindgren V; Xu M; Hoffman R
Cancer Res; 2007 Jul; 67(13):6417-24. PubMed ID: 17616702
[TBL] [Abstract][Full Text] [Related]
4. Chromatin-modifying agents permit human hematopoietic stem cells to undergo multiple cell divisions while retaining their repopulating potential.
Araki H; Yoshinaga K; Boccuni P; Zhao Y; Hoffman R; Mahmud N
Blood; 2007 Apr; 109(8):3570-8. PubMed ID: 17185465
[TBL] [Abstract][Full Text] [Related]
5. Expansion of human umbilical cord blood SCID-repopulating cells using chromatin-modifying agents.
Araki H; Mahmud N; Milhem M; Nunez R; Xu M; Beam CA; Hoffman R
Exp Hematol; 2006 Feb; 34(2):140-9. PubMed ID: 16459182
[TBL] [Abstract][Full Text] [Related]
6. Ex vivo expansion of human mobilized peripheral blood stem cells using epigenetic modifiers.
Saraf S; Araki H; Petro B; Park Y; Taioli S; Yoshinaga KG; Koca E; Rondelli D; Mahmud N
Transfusion; 2015 Apr; 55(4):864-74. PubMed ID: 25363624
[TBL] [Abstract][Full Text] [Related]
7. Behavior of CD34+ cells isolated from patients with polycythemia vera in NOD/SCID mice.
Ishii T; Zhao Y; Sozer S; Shi J; Zhang W; Hoffman R; Xu M
Exp Hematol; 2007 Nov; 35(11):1633-40. PubMed ID: 17764815
[TBL] [Abstract][Full Text] [Related]
8. Modification of hematopoietic stem cell fate by 5aza 2'deoxycytidine and trichostatin A.
Milhem M; Mahmud N; Lavelle D; Araki H; DeSimone J; Saunthararajah Y; Hoffman R
Blood; 2004 Jun; 103(11):4102-10. PubMed ID: 14976039
[TBL] [Abstract][Full Text] [Related]
9. The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon α 2a target JAK2V617F-positive progenitor and stem cells.
Lu M; Xia L; Li Y; Wang X; Hoffman R
Blood; 2014 Jul; 124(5):771-9. PubMed ID: 24869939
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of epigenetic modifiers on the expansion and maintenance of human cord blood stem/progenitor cells.
Mahmud N; Petro B; Baluchamy S; Li X; Taioli S; Lavelle D; Quigley JG; Suphangul M; Araki H
Biol Blood Marrow Transplant; 2014 Apr; 20(4):480-9. PubMed ID: 24374212
[TBL] [Abstract][Full Text] [Related]
11. Primary myelofibrosis marrow-derived CD14+/CD34- monocytes induce myelofibrosis-like phenotype in immunodeficient mice and give rise to megakaryocytes.
Manshouri T; Verstovsek S; Harris DM; Veletic I; Zhang X; Post SM; Bueso-Ramos CE; Estrov Z
PLoS One; 2019; 14(9):e0222912. PubMed ID: 31569199
[TBL] [Abstract][Full Text] [Related]
12. Cord blood stem cell expansion is permissive to epigenetic regulation and environmental cues.
Araki H; Baluchamy S; Yoshinaga K; Petro B; Petiwala S; Parajuli R; Milhem M; Lavelle D; DeSimone J; Mahmud N
Exp Hematol; 2009 Sep; 37(9):1084-95. PubMed ID: 19501128
[TBL] [Abstract][Full Text] [Related]
13. The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity.
James C; Mazurier F; Dupont S; Chaligne R; Lamrissi-Garcia I; Tulliez M; Lippert E; Mahon FX; Pasquet JM; Etienne G; Delhommeau F; Giraudier S; Vainchenker W; de Verneuil H
Blood; 2008 Sep; 112(6):2429-38. PubMed ID: 18612101
[TBL] [Abstract][Full Text] [Related]
14. A thrombopoietin receptor antagonist is capable of depleting myelofibrosis hematopoietic stem and progenitor cells.
Wang X; Haylock D; Hu CS; Kowalczyk W; Jiang T; Qiu J; Mosoyan G; He W; Marshall N; Mascarenhas J; Tarasova A; Brody J; Winkler D; Hoffman R
Blood; 2016 Jun; 127(26):3398-409. PubMed ID: 27114459
[TBL] [Abstract][Full Text] [Related]
15. Rationale for combination therapy in myelofibrosis.
Mascarenhas J
Best Pract Res Clin Haematol; 2014 Jun; 27(2):197-208. PubMed ID: 25189730
[TBL] [Abstract][Full Text] [Related]
16. Constitutive STAT5 phosphorylation in CD34+ cells of patients with primary myelofibrosis: Correlation with driver mutation status and disease severity.
Abbà C; Campanelli R; Catarsi P; Villani L; Abbonante V; Sesta MA; Barosi G; Rosti V; Massa M
PLoS One; 2019; 14(8):e0220189. PubMed ID: 31369569
[TBL] [Abstract][Full Text] [Related]
17. Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells.
Wang X; Hu CS; Petersen B; Qiu J; Ye F; Houldsworth J; Eng K; Huang F; Hoffman R
Blood Adv; 2018 Sep; 2(18):2378-2388. PubMed ID: 30242099
[TBL] [Abstract][Full Text] [Related]
18. Phenotypic characterization of malignant progenitor cells in patients with idiopathic myelofibrosis.
Bao Y; Hu W; Guo Y; Yang W
Hematol Oncol Stem Cell Ther; 2019 Sep; 12(3):146-154. PubMed ID: 30796884
[TBL] [Abstract][Full Text] [Related]
19. C-X-C motif chemokine 12 influences the development of extramedullary hematopoiesis in the spleens of myelofibrosis patients.
Wang X; Cho SY; Hu CS; Chen D; Roboz J; Hoffman R
Exp Hematol; 2015 Feb; 43(2):100-9.e1. PubMed ID: 25461253
[TBL] [Abstract][Full Text] [Related]
20. Immunoproteasome Genes Are Modulated in CD34
Di Rosa M; Giallongo C; Romano A; Tibullo D; Li Volti G; Musumeci G; Barbagallo I; Imbesi R; Castrogiovanni P; Palumbo GA
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32331228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
